Preimplantation Genetic Testing Market Size & Outlook, 2025-2033

Preimplantation Genetic Testing Market Size

The global preimplantation genetic testing market size was valued at USD 848.11 million in 2024 and is expected to grow from USD 905.87 million in 2025 to reach USD 1534.47 million by 2033, exhibiting a CAGR of 6.81% during the forecast period (2025-2033).

Preimplantation genetic testing (PGT) is increasingly integral to assisted reproductive technologies (ART), offering early detection of genetic abnormalities in embryos before implantation. Rising infertility rates, advancements in genetic screening technologies, and growing awareness of hereditary diseases drive the market's expansion. Couples seeking to prevent transmission of genetic disorders are turning to PGT as a proactive measure. Technological innovations, such as next-generation sequencing (NGS) and polymerase chain reaction (PCR), have enhanced the accuracy and efficiency of PGT, making it more accessible and reliable.

Additionally, the trend of delayed parenthood in developed countries has increased the demand for ART and associated genetic testing. Regulatory support and favourable reimbursement policies in regions like North America and Europe further bolster market growth. However, ethical considerations and the high cost of procedures may pose challenges. The PGT market is poised for substantial growth, reflecting broader shifts toward personalised medicine and preventive healthcare.

Current Market Trend

Integration of Ai and Automation in Pgt

The integration of artificial intelligence (AI) and automation in preimplantation genetic testing is transforming the field by improving diagnostic precision and laboratory efficiency. AI-driven algorithms enable more sophisticated analysis of complex genetic data, enhancing the accuracy of detecting chromosomal abnormalities and genetic mutations. Automation reduces manual labour and human error by streamlining workflows such as sample preparation, embryo imaging, and data reporting. For example, AI-assisted embryo imaging platforms use deep learning to evaluate embryo viability, supporting embryologists in selecting embryos with the highest implantation potential, thereby improving IVF success rates. Companies like CooperSurgical have recently introduced AI-powered PGT platforms, enabling faster turnaround and better diagnostic outcomes.

• For instance, in January 2025, CooperSurgical launched its AI-integrated genetic analysis system, offering enhanced precision and automation that accelerates testing timelines, reduces costs, and expands patient accessibility.

As AI and automation evolve, they will continue redefining reproductive genetics standards by delivering personalised, efficient testing solutions globally.

To get more insights about this report Download Free Sample Report

Preimplantation Genetic Testing Market Growth Factors

Rising Prevalence of Genetic Disorders

The growing global prevalence of genetic disorders is a key factor propelling demand for preimplantation genetic testing. According to the WHO, millions of people worldwide are affected by inherited conditions such as cystic fibrosis, thalassemia, sickle cell anaemia, and Tay-Sachs disease. PGT offers a preventive measure by enabling prospective parents to screen embryos for genetic mutations before implantation, significantly reducing the risk of transmitting hereditary diseases. Increased public awareness of genetic counselling and testing options has empowered families to make informed reproductive decisions.

• For example, Invitae Corporation expanded its PGT services in May 2024 by launching comprehensive panels targeting hereditary cancer syndromes and rare genetic disorders, reflecting rising demand. In March 2025, Invitae announced a partnership with leading fertility clinics in North America to offer combined genetic counselling and PGT, providing integrated care that addresses the growing need for hereditary disease prevention.

This rising demand is expected to continue driving the global PGT market forward.

Key Market Restraint

Ethical and Regulatory Challenges

Despite its benefits, the preimplantation genetic testing market faces significant ethical and regulatory obstacles. Moral concerns about embryo selection, the potential misuse of PGT for non-medical traits like gender or physical characteristics, and fears of “designer babies” generate ongoing debates. Regulatory frameworks vary widely worldwide, with some countries permitting PGT only for medical purposes, while others restrict or ban its use altogether. For instance, India allows PGT primarily for disease prevention but prohibits non-medical sex selection under the PCPNDT Act. These regulatory disparities complicate international service delivery and limit market expansion.

Additionally, the high cost of PGT procedures, often not covered by insurance, restricts access, especially in lower-income regions. The European Society of Human Reproduction and Embryology (ESHRE) issued updated ethical guidelines urging transparent policies and equitable access to PGT technologies, emphasising responsible use. Addressing these challenges requires harmonised regulations and public dialogue to ensure ethical growth of the PGT market.

Market Opportunity

Expansion in Emerging Markets

Emerging markets offer significant growth potential for the preimplantation genetic testing market due to rising infertility rates, greater awareness of genetic health, and improvements in healthcare infrastructure. Countries like India, China, Brazil, and parts of the Middle East are witnessing growing demand for assisted reproductive technologies (ART) combined with advanced genetic testing. In India, government initiatives such as the National Health Mission and the push for reproductive health awareness have spurred increased adoption of PGT.

• For example, in October 2024, Manipal Fertility launched a state-of-the-art genetic testing facility in Bangalore, equipped with next-generation sequencing and AI-powered analysis tools, to provide affordable PGT services tailored for the local population.

Similarly, China’s relaxation of the one-child policy and healthcare modernisation investments have opened new avenues for market expansion. Companies are tapping into large, underserved populations by adapting offerings to regional cultural and economic contexts, driving significant growth opportunities in these emerging markets.

Regional Analysis

North America continues to dominate the global preimplantation genetic testing market, holding the largest market share due to its advanced healthcare infrastructure, high IVF adoption rates, and stringent regulatory environment. The U.S., in particular, benefits from widespread availability of cutting-edge genetic testing technologies, strong R&D investments, and well-established fertility clinics. Additionally, increasing patient awareness about genetic disorders and personalised reproductive medicine further propels market demand. Government and private healthcare funding support innovation and accessibility, with expanded insurance coverage for fertility treatments in some states encouraging uptake.

U.s. Preimplantation Genetic Testing Market Trends

• The U.S. remains the largest market for preimplantation genetic testing, bolstered by its advanced healthcare infrastructure, high public awareness, and relatively favourable reimbursement policies for fertility treatments. Leading biotech companies like Natera, Inc. and Illumina, Inc. continue innovating AI-driven PGT platforms that enhance diagnostic precision and reduce turnaround times. Additionally, extensive collaborations between fertility clinics and genetic testing providers have improved service integration.
• Canada's preimplantation genetic testing market is witnessing steady growth, supported by its publicly funded healthcare system and rising awareness about genetic disorders. Increasing investments in reproductive health R&D foster innovative PGT technologies, with Canadian companies developing more accessible testing kits and counselling services. Continued government support for genetic research and patient education will drive market expansion.

Asia-Pacific Preimplantation Genetic Testing Market Trends

The Asia-Pacific region is the fastest-growing market for PGT, driven by expanding fertility clinics, rising infertility rates, and increasing awareness of genetic testing in countries like China, India, South Korea, and Japan. Government initiatives in China, such as healthcare modernisation and easing family planning policies, have spurred investments in assisted reproductive technologies. India’s growing middle class and increasing healthcare expenditure have encouraged the adoption of advanced reproductive diagnostics. Additionally, South Korea and Japan focus on integrating robotics and automation in IVF laboratories to enhance precision and efficiency. International collaborations and training programs are improving technical expertise and accelerating PGT market growth throughout the region.

• China is experiencing rapid growth in the preimplantation genetic testing market, propelled by rising infertility rates, expanding fertility clinics, and supportive government healthcare initiatives. The government’s “Healthy China 2030” plan includes reproductive health modernisation, fostering investments in advanced genetic diagnostics. Relaxation of family planning policies has also boosted demand for ART and PGT services. Partnerships between local and international biotech firms accelerate technology transfer and clinical adoption.
• India’s preimplantation genetic testing industry is rapidly expanding, driven by increasing infertility prevalence, growing awareness of genetic disorders, and improvements in healthcare infrastructure. The country’s largest fertility clinic chain, Indira IVF, operates over 150 centres nationwide, offering comprehensive PGT services with cutting-edge technologies as of 2024. Government initiatives aimed at reproductive health education and genetic counselling enhance patient outreach. Additionally, rising medical tourism for fertility treatments attracts international patients seeking affordable yet advanced PGT services.

Europe Preimplantation Genetic Testing Market Trends

Europe represents a significant and growing market for PGT, led by countries such as the UK, Germany, and France. The region's strict regulatory frameworks, enforced by agencies like the European Medicines Agency (EMA), ensure high standards for genetic testing and embryo selection. Public and private investments in reproductive health research continue to bolster innovation. The growing trend of cross-border fertility treatments within Europe is also boosting PGT demand, as patients seek specialised services with advanced genetic testing capabilities. Additionally, increasing collaborations between academic institutions and biotech companies foster the development of AI-driven diagnostic tools, enhancing precision medicine approaches in PGT.

• The UK’s well-regulated preimplantation genetic testing market benefits from oversight by the Human Fertilisation and Embryology Authority (HFEA), ensuring ethical and quality standards. The country’s high adoption rate of advanced reproductive technologies is complemented by government-backed initiatives promoting fertility health and personalised medicine. The NHS has also begun pilot programs integrating PGT into publicly funded fertility treatments, expanding accessibility. Research collaborations between academia and industry continue to drive innovation in genetic diagnostics.
• Germany’s PGT market is expanding steadily, driven by a robust healthcare system and strong emphasis on research and development in medical and genetic technologies. Government funding for innovation and clinical trials supports increasing demand for genetic screening in reproductive health. Germany’s strict regulatory standards ensure high-quality testing, fostering trust among patients and clinicians. The country’s well-established biotech industry also contributes to developing next-generation reagents and consumables for PGT.

Procedure Insights

Preimplantation Genetic Diagnosis (PGD) is dominant in the PGT market, primarily due to its critical role in identifying specific genetic mutations in embryos before implantation. This procedure is especially vital for couples with a known history of genetic disorders, as it enables the selection of embryos free from particular hereditary conditions. The increasing prevalence of genetic diseases and the rising demand for personalised medicine contribute to the growth of this segment. Advancements in genetic testing technologies have further enhanced the accuracy and reliability of PGD, making it a preferred choice among healthcare providers and patients.

Product Insights

Reagents and consumables constitute the largest share in the product segment, driven by their essential role in conducting genetic tests. These include DNA amplification kits, sequencing reagents, and other laboratory essentials required for PGT procedures. The recurring nature of these products ensures a steady demand, and continuous innovations in reagent formulations have improved test sensitivity and specificity. As the number of PGT procedures increases globally, the demand for high-quality reagents and consumables is expected to rise correspondingly. Additionally, manufacturers are developing next-generation consumables compatible with automated and high-throughput platforms, which streamline laboratory workflows and enhance reproducibility.

Technology Insights

NGS technology has revolutionised the field of genetic testing by allowing comprehensive genome analysis with high accuracy and throughput. In the context of PGT, NGS detects various genetic abnormalities, including single-gene disorders and chromosomal aneuploidies. Its ability to provide detailed genetic information makes it invaluable for embryo screening. The decreasing cost of sequencing and the development of user-friendly platforms have facilitated the adoption of NGS in clinical settings, thereby driving the growth of this segment. Furthermore, portable and benchtop NGS devices introduced in 2024 have increased accessibility, particularly in emerging markets, broadening the user base and enhancing real-time decision-making during IVF cycles.

Application Insights

Aneuploidy screening is a critical application of PGT, focusing on detecting abnormal numbers of chromosomes in embryos, which can lead to conditions like Down syndrome. This screening enhances the success rates of IVF by ensuring only chromosomally normal embryos are implanted. The increasing maternal age and associated risk of chromosomal abnormalities have heightened the demand for aneuploidy screening. Technological advancements have improved the accuracy of these tests, making them a standard component of fertility treatments. Furthermore, the development of non-invasive PGT methods for aneuploidy screening is gaining momentum, minimising embryo biopsy risks and improving patient acceptance.

End-User Insights

Fertility centres are the primary end-users of PGT services, as they integrate genetic testing into their IVF protocols to improve pregnancy outcomes. These centres often have specialised laboratories and trained personnel to conduct PGT, ensuring timely and accurate results. The growing number of fertility clinics worldwide, coupled with increasing awareness of genetic testing benefits, has solidified the dominance of this segment. Moreover, collaborations between fertility centres and genetic testing companies have streamlined the testing process, enhancing service offerings. The trend toward centralised PGT laboratories serving multiple clinics also increases efficiency and lowers costs, fostering market growth.

Company Market Share

The PGT market is characterised by intense competition, with key players focusing on technological advancements, strategic partnerships, and mergers to strengthen their market position. 

Illumina, Inc.: As a leading player in the PGT market, Illumina offers a comprehensive suite of genetic testing solutions, including the VeriSeq PGS and MiSeq systems. The company's strong global presence and continuous innovation in sequencing technologies have solidified its market position. 

• In November 2023, Illumina launched the VeriSeq PGS 3.0, enhancing accuracy and efficiency in embryo selection for IVF.

List of key players in Preimplantation Genetic Testing Market

1. Oxford Gene Technology
2. Thermo Fisher Scientific Inc.
3. SciGene Corporation
4. Agilent Technologies Inc.
5. PerkinElmer Inc.
6. Coopersurgical Inc.
7. Abbott Laboratories
8. Illumina Inc.
9. Natera Inc
10. Yikon Genomics

To get more findings about this report Download Market Share

Recent Developments

• September 2024- Monash IVF Group agreed to a $56 million settlement in a class-action lawsuit involving over 700 patients. The case centred on a faulty non-invasive PGT-A test that misclassified embryos, leading to missed opportunities for patients to have biological children.
• January 2024- Orchid Health introduced the first commercially available whole genome sequencing service for specific diseases in preimplantation embryos, enhancing the precision of genetic screening in IVF procedures.